J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
- Market Cap ₹ 29,590 Cr.
- Current Price ₹ 1,907
- High / Low ₹ 1,940 / 875
- Stock P/E 57.6
- Book Value ₹ 175
- Dividend Yield 0.47 %
- ROCE 22.4 %
- ROE 17.6 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 31.7%
Cons
- Stock is trading at 10.9 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
802 | 866 | 1,022 | 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | 3,385 | |
701 | 760 | 874 | 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | 2,522 | |
Operating Profit | 101 | 106 | 148 | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 862 |
OPM % | 13% | 12% | 14% | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% | 25% |
789 | 27 | -27 | 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 25 | |
Interest | 24 | 4 | 6 | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 49 |
Depreciation | 22 | 25 | 28 | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 129 |
Profit before tax | 843 | 104 | 87 | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 709 |
Tax % | 20% | 23% | 30% | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% | |
678 | 79 | 62 | 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 514 | |
EPS in Rs | 40.02 | 4.69 | 3.63 | 5.92 | 9.58 | 10.85 | 8.28 | 12.05 | 17.60 | 28.98 | 24.93 | 26.48 | 33.18 |
Dividend Payout % | 51% | 32% | 41% | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 17% |
3 Years: | 21% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 31% |
3 Years: | 16% |
TTM: | 26% |
Stock Price CAGR | |
---|---|
10 Years: | 38% |
5 Years: | 62% |
3 Years: | 40% |
1 Year: | 79% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 18% |
3 Years: | 20% |
Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 |
Reserves | 953 | 1,003 | 1,026 | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 | 2,701 |
71 | 50 | 93 | 127 | 193 | 49 | 29 | 26 | 29 | 45 | 55 | 572 | 437 | |
157 | 230 | 215 | 365 | 270 | 262 | 294 | 286 | 349 | 376 | 412 | 495 | 645 | |
Total Liabilities | 1,198 | 1,300 | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,799 |
276 | 334 | 311 | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,901 | 1,917 | |
CWIP | 39 | 5 | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 72 |
Investments | 302 | 398 | 500 | 552 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 315 |
581 | 563 | 494 | 552 | 594 | 580 | 674 | 699 | 743 | 894 | 1,293 | 1,385 | 1,495 | |
Total Assets | 1,198 | 1,300 | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,547 | 3,799 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
880 | 84 | -14 | 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | |
-261 | -116 | -142 | -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | |
-526 | -31 | 12 | -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | |
Net Cash Flow | 93 | -63 | -144 | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 62 | 81 | 84 | 84 | 82 | 72 | 78 | 68 | 71 | 70 | 84 | 67 |
Inventory Days | 117 | 104 | 120 | 122 | 146 | 138 | 145 | 149 | 159 | 181 | 178 | 134 |
Days Payable | 51 | 60 | 54 | 63 | 71 | 68 | 75 | 72 | 97 | 97 | 97 | 75 |
Cash Conversion Cycle | 128 | 124 | 150 | 143 | 158 | 142 | 148 | 146 | 133 | 153 | 164 | 127 |
Working Capital Days | 98 | 80 | 99 | 56 | 96 | 88 | 101 | 97 | 87 | 99 | 127 | 102 |
ROCE % | 11% | 8% | 13% | 13% | 15% | 14% | 11% | 18% | 23% | 33% | 23% | 22% |
Documents
Announcements
- Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 8h
- Disclosure Under Regulation 30 Of The SEBI (LODR), Regulations, 2015 26 Apr
- Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For Financial Year 2023-24 16 Apr
- Compliance Certificate Under Regulation 7(3) For The Year Ended March 31, 2024 12 Apr
- Announcement under Regulation 30 (LODR)-Change in Directorate 8 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Feb 2024Transcript PPT REC
-
Dec 2023Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Revenue Split H1FY24
Domestic Formulations - 55%
Export Formulations - 30%
Contract Manufacturing - 13%
APIs - 2% [1]